Where does Chunghwa Chemical Synthesis & Biotech Co. Ltd. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Chunghwa Chemical Synthesis & Biotech Co. Ltd. ranks #31,208 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Chunghwa Chemical Synthesis & Biotech Co. Ltd. hold?

Chunghwa Chemical Synthesis & Biotech Co. Ltd. holds 8 US utility patents granted between 2017 and 2024, spanning 9 technology areas.

What is Chunghwa Chemical Synthesis & Biotech Co. Ltd.'s Innovation Score?

Chunghwa Chemical Synthesis & Biotech Co. Ltd. has an Innovation Score of 32.2 out of 100 (40th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Chunghwa Chemical Synthesis & Biotech Co. Ltd. focus on?

Chunghwa Chemical Synthesis & Biotech Co. Ltd.'s top technology area is C07D (Heterocyclic Compounds) with 4 patents, ranking #1,646 of 3,165 assignees active in that subclass. Grants appear in 9 CPC subclasses total.

Is Chunghwa Chemical Synthesis & Biotech Co. Ltd.'s patent grant rate increasing or decreasing?

Chunghwa Chemical Synthesis & Biotech Co. Ltd.'s recent grant velocity is +67% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Chunghwa Chemical Synthesis & Biotech Co. Ltd.'s patents?

Chunghwa Chemical Synthesis & Biotech Co. Ltd.'s patents average 12.3 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Chunghwa Chemical Synthesis & Biotech Co. Ltd.

Q: How is the Chunghwa Chemical Synthesis & Biotech Co. Ltd. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO PatentsView assignee record - 8 granted patents across 9 technology areas, recorded in grant years 2017–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Chunghwa ranks #31,208 of 49,997 tracked US assignees by granted-patent volume, with 8 patents across 9 technology areas.

#31,208
of 49,997 US assignees by volume: 40th percentile
by Innovation Score (32.2/100): 12.3
avg claims per patent: +67%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R31208 · Foreign Corporation #31,208 · 8 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 8 grants
MID-PACK #31,208/49,997
PHOTO-FINISH Christiana Care…
CPC-NARROW C07D · 9 areas
INNOV-THIN 32.2/100
CLAIMS-RICH 12.3 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-SURGE +67% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Christiana Care Health System, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Chunghwa’s 32.2 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 7.6 pts (24%) Velocity 6.7 pts (21%) Breadth 10.6 pts (33%) Claim depth 7.4 pts (23%)

Qualcomm Incorporated · highest

85
Chunghwa Chemical… · this assignee

32
3D Lighting… · lowest

7

What this shows Chunghwa's Innovation Score is 32.2/100 (40th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Chunghwa?

Each dot is one of Chunghwa’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Chunghwa’s own 12.3 claims/patent is at or below the 14.0 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Chunghwa vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Chunghwa's grants concentrate

Chunghwa Chemical Synthesis & Biotech Co. Ltd. is a focused PatentsView assignee: 9 CPC subclasses with 50% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2021 (2 grants) versus a trough of 1 in 2017. By volume, Chunghwa sits between Christiana Care Health System, Inc. and Cisbio Bioassays.

Chunghwa's three-year grant acceleration

Chunghwa Chemical Synthesis & Biotech Co. Ltd. shows 3 grants in 2022–2024 against only 3 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Christiana Care H…

8
Chulalongkorn Uni…

8
Chun Kuang Optics

8
Chung-hsin Electr…

8
Cimc Containers H…

8
Cinna

8
Cireca Theranosti…

8
Cisbio Bioassays

8
Chunghwa Chemical… ◀

8

What this shows Chunghwa holds 8 patents at rank #31,166, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Chunghwa

By rank, the assignees closest to #31,166 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Chunghwa's primary technology class.

Chunghwa's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

32 40th percentile higher than 40% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2017–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table

Chunghwa Chemical Synthesis & Biotech Co. Ltd. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2017	1	12.5%
2018	1	12.5%
2019	1	12.5%
2021	2	25.0%
2022	1	12.5%
2023	1	12.5%
2024	1	12.5%

Which technologies does Chunghwa Chemical Synthesis & Biotech Co. Ltd. patent most?

C07D - Heterocyclic Compounds 4

C07K - Peptides 3

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 1

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 1

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 1

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 1

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 1

C11B - Producing, e.g. BY Pressing RAW Materials OR BY Extraction From Waste Materials, Refining OR Preserving Fats, Fatty Substances, e.g. Lanolin, Fatty Oils OR WAXES; Essential OILS; Perfumes 1

C07C - Acyclic OR Carbocyclic Compounds 1

Top 9 of 9 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Chunghwa Chemical Synthesis & Biotech Co. Ltd.'s patent record in context - here's where to go next.

Chunghwa Chemical Synthesis & Biotech Co. Ltd.'s lead technology class is C07D (Heterocyclic Compounds), 50% of its portfolio - see every assignee active in that class. Explore C07D
Ranked #31,208 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Chunghwa Chemical Synthesis & Biotech Co. Ltd. against Christiana Care Health System, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 32.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.